Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/22 Issuer sale

Chief Technology Officer

280,373 0.1193%
29/03/22 Tax

Executive/Senior Manager

68,414 0.0293%
29/03/22 Tax

Controller/Auditor

965 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.8B
-0.62%-2.71%+39.30%+114.07% 1,025B
-2.30%-4.44%+39.03%+66.07% 623B
-0.63%-1.96%+6.36%+74.38% 459B
-1.03%-2.82%+59.56%+39.69% 355B
-0.03%-3.96%+23.63%+39.35% 336B
-1.58%-0.76%+13.50%+25.77% 270B
-2.02%-2.97%-3.25%+8.38% 247B
-3.38%+0.30%+36.44%+51.54% 220B
-1.04%-1.46%+32.70%+96.82% 183B
Average -1.26%-1.89%+27.47%+57.34% 413.14B
Weighted average by Cap. -1.24%-2.11%+30.51%+69.30%
Logo Endo International plc
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116